The active triad is the major focus for the regulated reduction of AChE in patients with acetylcholine deficiency, such as those with Alzheimer’s disease or myasthenia gravis, which is described by varying muscle weakness and exhaustion as a result of a loss of receptors. This evidence concerns the gene ACHE and Alzheimer disease.